Medpace Holdings has seen its share price move a long way in recent years, which puts the focus squarely on whether the current valuation lines up with the cash the business can generate. With the stock recently closing at US$656.77, the key issue is how that market price stacks up against the cash flows implied by its underlying operations.
- Over the past 5 years, Medpace Holdings has delivered a total return of 197.2%, which raises the question of whether that share price performance still reflects the cash the business is expected to produce.
- The company runs a contract research model that can convert project wins into relatively visible service revenue, which may support more predictable cash flow patterns and makes a cash-flow based valuation especially relevant.
- If you'd rather focus on earnings, this one's for you. See why Medpace Holdings's 35.5x P/E tells a different valuation story.
The stock's next move may depend on whether the current share price is fully explained by the intrinsic value suggested by Medpace Holdings' cash flows.
If you are comparing Medpace Holdings with other opportunities that also depend on cash generation, it can be helpful to review it alongside 35 high quality undervalued stocks.
Where Does Medpace Holdings Sit on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash Medpace Holdings can return to shareholders over time. Latest twelve month free cash flow sits at about $672.8 million, which gives you a solid cash base rather than a story that depends only on distant projections. Analysts and internal estimates used in this DCF assume that free cash flow continues growing over the coming decade, then moderates into a slower second stage.
Projected free cash flow reaches the low $900 million range by 2030, with later years relying more on incremental increases than big step changes. On those assumptions, the DCF output suggests an intrinsic value that is broadly in line with the recent share price of $656.77, so the current market tag already reflects a meaningful portion of the expected cash generation. For anyone weighing Medpace Holdings against other options, the key question is how comfortable you are with those medium term cash flow expectations and the implied return profile at today’s price. Find out what Medpace Holdings could be worth using our Discounted Cash Flow (DCF) estimate.
The Medpace Holdings Narrative: What Would Justify Today's Price?
Narratives for Medpace Holdings pick up where this valuation question leaves off by spelling out what patterns in future growth, margins and earnings would need to play out for the share price to sit meaningfully above or below today’s level. Each scenario lays out the assumptions behind its view of fair value in plain terms, so you can compare those expectations with Medpace Holdings' actual results as they are released over time on Simply Wall St's Community page.
Community views on Medpace Holdings pull in different directions, with one camp seeing more value left in the current price and the other worrying about how much optimism is already priced in.
Bull case: 10% undervalued
"Record net new business awards in Q2 2026, together with management’s decision to keep growing headcount at a high single digit rate..."
Discover why this Narrative puts Medpace Holdings at 10% undervalued.
Bear case: 23% overvalued
"Most customers can terminate a clinical-trial contract without cause on 30 days’ notice, and Medpace is generally paid only for work already completed..."
Explore why this Narrative puts Medpace Holdings at 23% overvalued.
One more piece of the Medpace Holdings story to check
Valuation only tells part of the picture for Medpace Holdings, because internal checks have also highlighted specific risk factors that deserve a closer look before you commit fresh capital. Take a closer look at 1 warning sign before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com